Late Manifestation of Subclinical Hyperthyroidism After Goitrogenesis in an Index Patient with a N670S TSH Receptor Germline Mutation Masquerading as TSH Receptor Antibody Negative Graves’ Disease

 

 Buy Article Permissions and Reprints

Abstract

In 27 families with familial non-autoimmune hyperthyroidism (FNAH) reported up to date, the onset of hyperthyroidism varies from 18 months to 60 years. Also the manifestation of goitres is variable in these families. A 74-year-old woman first presented at the age of 69 years with tachyarrhythmia and hypertension. After initial treatment of her hypertension and oral anticoagulation for her intermittent atrial fibrillation, a thyroid workup revealed a suppressed TSH and normal fT3 and fT4. TPO, TSH receptor (TSHR), and thyroglobulin antibodies were negative. Thyroid ultrasound revealed a thyroid volume of 102 ml with several nodules with diameters of up to 2.6 cm right and up to 1.8 cm left. Scintigraphy showed a homogeneous Technetium-99 m (^99 mTc) uptake of 1.27%. She was subsequently treated with 1 GBq radioiodine (¹³¹I). At the age of 74, her thyroid function was normal and her thyroid volume decreased to 90 ml. Because of the diffuse ^99 mTc uptake and the negative TPO, TSHR, and thyroglobulin antibodies, genetic analysis of her TSHR gene was performed, in spite of her negative family history for hyperthyroidism. Sequencing revealed a N670S TSHR germline mutation. Previous in vitro characterisation of this TSHR mutation suggests a weak constitutive activity, yet the experimental data are ambiguous. This case illustrates the necessity to analyse patients with hyperthyroidism accompanied by diffuse ^99 mTc uptake and negative TPO, TSHR, and thyroglobulin antibodies for TSHR germline mutations. Moreover, it demonstrates that TSHR germline mutations may first lead to longstanding nodular goitrogenesis before the late manifestation of subclinical hyperthyroidism.

• References

• 1 Miehle K, Paschke R. Therapy of hyperthyroidism. Exp Clin Endocrinol Diabetes 2003; 111: 305-318
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Vos XG, Smit N, Endert E, Tijssen JGP, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves hyperthyroidism: a prospective study. Clin Endocrinol 2008; 69: 311-317
  CrossrefPubMedGoogle Scholar
• 3 Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism. J Clin Endocrinol Metab 1987; 65: 659-664
  CrossrefPubMedGoogle Scholar
• 4 Meller J, Jauho A, Hüfner M, Gratz S, Becker W. Disseminated thyroid autonomy or Graves’ disease: reevaluation by a second generation TSH receptor antibody assay. Thyroid 2000; 10: 1073-1079
  CrossrefPubMedGoogle Scholar
• 5 Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter. Horm Metab Res 2001; 33: 504-507
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Führer D, Lachmund P, Nebel I-T, Paschke R. The thyrotropin receptor mutation database: update 2003. Thyroid 2003; 13: 1123-1126
  CrossrefPubMedGoogle Scholar
• 7 Gozu HI, Mueller S, Bircan R, Krohn K, Ekinci G, Yavuzer D, Sargin H, Ones T, Gezen C, Orbay E, Cirakoglu B, Paschke R. A new silent germline mutation of the TSH receptor: coexpression in a hyperthyroid family member with a second activating somatic mutation. Thyroid 2008; 18: 499-508
  CrossrefPubMedGoogle Scholar
• 8 Lueblinghoff J, Eszlinger M, Jaeschke H, Mueller S, Bircan R, Gozu H, Sancak S, Akalin S, Paschke R. Shared sporadic and somatic thyrotropin receptor mutations display more active in vitro activities than familial thyrotropin receptor mutations. Thyroid 2011; 21: 221-229
  CrossrefPubMedGoogle Scholar
• 9 Trülzsch B, Krohn K, Wonerow P, Paschke R. DGGE is more sensitive for the detection of somatic point mutations than direct sequencing. Biotechniques 1999; 27: 266
  PubMedGoogle Scholar
• 10 Tonacchera M, Van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996; 81: 547-554
  CrossrefPubMedGoogle Scholar
• 11 Mueller S, Gozu HI, Bircan R, Jaeschke H, Eszlinger M, Lueblinghoff J, Krohn K, Paschke R. Cases of borderline in vitro constitutive thyrotropin receptor activity: how to decide whether a thyrotropin receptor mutation is constitutively active or not?. Thyroid 2009; 19: 765-773
  CrossrefPubMedGoogle Scholar
• 12 Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 1990; 89: 602-608
  CrossrefPubMedGoogle Scholar
• 13 Wallaschofski H, Müller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res 2002; 34: 36-39
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Jaeschke H, Mueller S, Eszlinger M, Paschke R. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas. Clin Endocrinol 2010; 73: 815-820
  CrossrefPubMedGoogle Scholar
• 15 Mueller S, Jaeschke H, Paschke R. Current standards, variations, and pitfalls for the determination of constitutive TSHR activity in vitro. Meth Enzymol 2010; 485: 421-436
  PubMedGoogle Scholar
• 16 Neumann S, Krause G, Claus M, Paschke R. Structural determinants for g protein activation and selectivity in the second intracellular loop of the thyrotropin receptor. Endocrinology 2005; 146: 477-485
  PubMedGoogle Scholar
• 17 Grasberger H, Van Sande J, Hag-Dahood Mahameed A, Tenenbaum-Rakover Y, Refetoff S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab 2007; 92: 2816-2820
  CrossrefPubMedGoogle Scholar
• 18 Kero J, Ahmed K, Wettschureck N, Tunaru S, Wintermantel T, Greiner E, Schütz G, Offermanns S. Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development. J Clin Invest 2007; 117: 2399-2407
  CrossrefPubMedGoogle Scholar
• 19 Winkler F, Kleinau G, Tarnow P, Rediger A, Grohmann L, Gaetjens I, Krause G, l’Allemand D, Grüters A, Krude H, Biebermann H. A new phenotype of nongoitrous and nonautoimmune hyperthyroidism caused by a heterozygous thyrotropin receptor mutation in transmembrane helix 6. J Clin Endocrinol Metab 2010; 95: 3605-3610
  CrossrefPubMedGoogle Scholar
• 20 Lueblinghoff J, Mueller S, Sontheimer J, Paschke R. Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism. J Endocrinol Invest 2010; 33: 228-233
  PubMedGoogle Scholar